Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
- Lukas Jörg,
- Tatjana Pecaric-Petkovic,
- Stephan Reichenbach,
- Michael Coslovsky,
- Odile Stalder,
- Werner Pichler,
- Oliver Hausmann
Clin Exp Allergy 2017 Nov 22. Epub 2017 Nov 22.
Department of Rheumatology, Immunology and Allergology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Background: Omalizumab has been shown to be effective in treating chronic spontaneous urticaria (CSU). The reduction of FcεRI receptor density on the surface of basophils and mast cells is thought to play a major role in its effectiveness. We conducted a double-blind, randomized, placebo-controlled trial to investigate the mode of action of omalizumab in patients with antihistamine-resistant CSU. Read More